Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Abatacept in IgG4-Related Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03669861
Recruitment Status : Active, not recruiting
First Posted : September 13, 2018
Last Update Posted : September 16, 2020
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Stone, John H, M.D., M.P.H, Massachusetts General Hospital

Brief Summary:
This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).

Condition or disease Intervention/treatment Phase
IgG4-related Disease Drug: Abatacept Phase 2

Detailed Description:

After obtaining informed consent, all screening procedures and tests establishing eligibility will be performed on the initial screening visit. Subjects determined to be eligible at screening will receive an initial subcutaneous dose of abatacept (125mg), which will be continued weekly for a total of up to 24 doses (24 weeks). Steroid therapy must be tapered off and discontinued over a 4 week period (taper must be completed no later than week 4). Should patients be deemed to have worsening disease or failing therapy at 4 weeks then a trial of steroids can be considered.

Subjects will return on weeks 1, 2, 4, 8, 12, 16, 20, and 24 while on treatment for their injections, and for the scheduled safety and disease response assessments. Subjects will be allowed to self-administer their injections at home. The full treatment period is 24 doses given weekly for 24 weeks. Subjects who are not able to be tapered off corticosteroids or who require reinstitution of corticosteroid therapy at any time during the study will be counted as treatment failures, but may continue on study. Should the IgG4-RD responder index fail to improve by 8 weeks or should there be development of new organ failure at 4 weeks, patient's will be deemed treatment failure and can begin corticosteroid or alternative immunosuppressive therapy at the Investigator's discretion. Those who require rituximab or who require addition of other oral immunosuppressives will be counted as treatment failures and will terminate the study.

All subjects completing the treatment period will have follow up visits off protocolized treatment at 28 and 36 weeks. All adverse events (including serious adverse events (AEs) and deaths) and use of concomitant medication information will be collected throughout the study from screening through study termination. Subjects developing treatment-emergent adverse events or clinically significant safety lab abnormalities will be followed until resolution or until stabilization of the adverse events/abnormalities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study
Actual Study Start Date : November 13, 2018
Estimated Primary Completion Date : November 15, 2020
Estimated Study Completion Date : December 20, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Abatacept

Arm Intervention/treatment
Experimental: Abatacept
To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
Drug: Abatacept
Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
Other Name: Orencia




Primary Outcome Measures :
  1. Treatment Response [ Time Frame: 36 weeks ]
    effect of weekly subcutaneous (SC) administration of abatacept on complete remission


Secondary Outcome Measures :
  1. Disease Response [ Time Frame: 36 weeks ]
    assess the effect of abatacept on disease response and remission

  2. Disease remission: complete remission [ Time Frame: 36 weeks ]
    Percentage of patients achieving disease remission

  3. Disease remission: time [ Time Frame: 36 weeks ]
    Time to remission

  4. Disease remission: flares over time per subject [ Time Frame: 36 weeks ]
    number of disease flares per subject over time

  5. Disease remission: flares per subject [ Time Frame: 36 weeks ]
    Number of flares per subject during follow-up



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Are male or female 18 years of age or older
  2. Meet the American College of Rheumatology (ACR)/EULAR 2018 Classification Criteria for IgG4-RD
  3. Have active disease based on an IgG4-RD Responder Index (RI) ≥2 at screening with disease manifestation in at least one organ system excluding lymph nodes at screening
  4. May or may not have received prior IgG4-RD therapy
  5. Must be willing to taper off any systemic corticosteroid therapy within 4 weeks of first dose of trial drug.
  6. Must be able and willing to discontinue any immunosuppressive agent at screening (e.g. methotrexate, mycophenolate mofetil, 6-mercaptopurine, tacrolimus, cyclophosphamide or azathioprine).
  7. No history of severe allergic reactions to monoclonal antibodies.
  8. Are able and willing to complete the entire study according to the study schedule.
  9. Are willing to forego other forms of experimental treatment during the study.
  10. Are able to provide written informed consent.

Exclusion Criteria:

  1. History or evidence of a clinically unstable/uncontrolled disorder, condition or disease (including but not limited to cardiopulmonary, oncologic, renal, hepatic, metabolic, hematologic or psychiatric) other than IgG4-RD that, in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion.
  2. Malignancy within 5 years (except successfully treated in situ cervical cancer, resected squamous cell or basal cell carcinoma of the skin, or prostate cancer with no recurrence ≥3 years following prostatectomy).
  3. Liver disease: Acute or chronic non-IgG4-related liver disease deemed sufficiently severe to impair their ability to participate in the trial.
  4. Uncontrolled disease: evidence of another uncontrolled condition, including drug and alcohol abuse, which could interfere with participation in the trial according to the protocol.
  5. Presence of recurrent or chronic infections, defined as ≥3 infections requiring antimicrobials over the past 6 months prior to screening.
  6. Active infection requiring hospitalization or treatment with parenteral antimicrobials within the 30 days prior to randomization.
  7. Prior use of rituximab (or other B cell depleting agents) within 6 months of enrollment unless B cells have been demonstrated to have repopulated.
  8. Use of any investigational agent within 5 half-lives of the agent (or 6 months if the half-life is unknown) prior to enrollment.
  9. White blood cell count < 2.5 x 103/µL.
  10. Absolute neutrophil count (ANC) < 1.0 x 103/µL.
  11. IgG4-related renal disease with serum creatinine >2.0 mg/dL.
  12. Hemoglobin < 10 g/dL.
  13. Platelet count < 75 x 109/L.
  14. Known positive result for HIV I or II antibody, hepatitis B surface antigen, hepatitis B core antibody or hepatitis C antibody.
  15. Has received live vaccines within 4 weeks of enrollment.
  16. Inability to communicate reliably with the investigator.
  17. Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to end of study (EOS) visit.
  18. Positive pregnancy test at screening or during the study.
  19. Subjects who do not agree to use medically acceptable methods of contraception.
  20. Male patient with a pregnant partner who is not willing to use a condom during the treatment and up to end of study (EOS)visit.
  21. Known or suspected sensitivity to mammalian cell-derived products or any components of the study drug.
  22. History of alcohol and/or substance abuse within 12 months prior to screening.
  23. Unable or unwilling to partake in follow-up assessments or required protocol procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03669861


Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: John H Stone, MD Massachusetts General Hospital and Harvard Medical School
Layout table for additonal information
Responsible Party: Stone, John H, M.D., M.P.H, Director, Division of Rheumatology, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT03669861    
Other Study ID Numbers: IM101-744
First Posted: September 13, 2018    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Individual participant data will be shared upon request - without personal health information - following completion of the analysis. Inquiries should be directed to the Principal Investigator.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Immunoglobulin G4-Related Disease
Autoimmune Diseases
Immune System Diseases
Abatacept
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents